Literature DB >> 21193525

Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells.

Kristin G Nørsett1, Islay Steele, Cedric Duval, Stephen J Sammut, Senthil V M Murugesan, Susan Kenny, Lucille Rainbow, Rod Dimaline, Graham J Dockray, D Mark Pritchard, Andrea Varro.   

Abstract

Plasminogen activator inhibitor (PAI)-1 is associated with cancer progression, fibrosis and thrombosis. It is expressed in the stomach but the mechanisms controlling its expression there, and its biological role, are uncertain. We sought to define the role of gastrin in regulating PAI-1 expression and to determine the relevance for gastrin-stimulated cell migration and invasion. In gastric biopsies from subjects with elevated plasma gastrin, the abundances of PAI-1, urokinase plasminogen activator (uPA), and uPA receptor (uPAR) mRNAs measured by quantitative PCR were increased compared with subjects with plasma concentrations in the reference range. In patients with hypergastrinemia due to autoimmune chronic atrophic gastritis, there was increased abundance of PAI-1, uPA, and uPAR mRNAs that was reduced by octreotide or antrectomy. Immunohistochemistry revealed localization of PAI-1 to parietal cells and enterochromaffin-like cells in micronodular neuroendocrine tumors in hypergastrinemic subjects. Transcriptional mechanisms were studied by using a PAI-1-luciferase promoter-reporter construct transfected into AGS-G(R) cells. There was time- and concentration-dependent increase of PAI-1-luciferase expression in response to gastrin that was reversed by inhibitors of the PKC and MAPK pathways. In Boyden chamber assays, recombinant PAI-1 inhibited gastrin-stimulated AGS-G(R) cell migration and invasion, and small interfering RNA treatment increased responses to gastrin. We conclude that elevated plasma gastrin concentrations are associated with increased expression of gastric PAI-1, which may act to restrain gastrin-stimulated cell migration and invasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193525      PMCID: PMC3174540          DOI: 10.1152/ajpgi.00527.2010

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  40 in total

1.  Stimulation of the gastrin-cholecystokinin(B) receptor promotes branching morphogenesis in gastric AGS cells.

Authors:  A Pagliocca; L E Wroblewski; F J Ashcroft; P J Noble; G J Dockray; A Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-08       Impact factor: 4.052

2.  Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1.

Authors:  Simon Almeida-Vega; Krista Catlow; Susan Kenny; Rod Dimaline; Andrea Varro
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-12       Impact factor: 4.052

3.  Changes in gene expression of gastric mucosa during therapeutic acid inhibition.

Authors:  Kristin G Nørsett; Astrid Laegreid; Waclaw Kusnierczyk; Mette Langaas; Sonja Ylving; Reidar Fossmark; Simen Myhre; Sture Falkmer; Helge L Waldum; Arne K Sandvik
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-07       Impact factor: 2.566

Review 4.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

5.  Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells: regulation by gastrin.

Authors:  F Watson; R S Kiernan; D G Deavall; A Varro; R Dimaline
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

6.  Gastrin-cholecystokinin(B) receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor.

Authors:  A Varro; P J Noble; L E Wroblewski; L Bishop; G J Dockray
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

7.  Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression.

Authors:  K Takeda; T Ichiki; T Tokunou; N Iino; S Fujii; A Kitabatake; H Shimokawa; A Takeshita
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-05       Impact factor: 8.311

8.  Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression.

Authors:  Lydia E Wroblewski; David M Pritchard; Stuart Carter; Andrea Varro
Journal:  Biochem J       Date:  2002-08-01       Impact factor: 3.857

9.  Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin.

Authors:  Andrea Varro; Elaine Hemers; Debbie Archer; Adelina Pagliocca; Chris Haigh; Suhail Ahmed; Rod Dimaline; Graham J Dockray
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

10.  Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.

Authors:  A C Keates; S Tummala; R M Peek; E Csizmadia; B Kunzli; K Becker; P Correa; J Romero-Gallo; M B Piazuelo; S Sheth; C P Kelly; S C Robson; S Keates
Journal:  Infect Immun       Date:  2008-06-02       Impact factor: 3.441

View more
  18 in total

1.  Gastrin stimulates MMP-1 expression in gastric epithelial cells: putative role in gastric epithelial cell migration.

Authors:  J Dinesh Kumar; Islay Steele; Andrew R Moore; Senthil V Murugesan; Zoltan Rakonczay; Viktoria Venglovecz; D Mark Pritchard; Rodney Dimaline; Laszlo Tiszlavicz; Andrea Varro; Graham J Dockray
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-05-14       Impact factor: 4.052

2.  Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.

Authors:  Malcolm Boyce; Andrew R Moore; Liv Sagatun; Bryony N Parsons; Andrea Varro; Fiona Campbell; Reidar Fossmark; Helge L Waldum; D Mark Pritchard
Journal:  Br J Clin Pharmacol       Date:  2016-11-21       Impact factor: 4.335

3.  Gastrin receptor pharmacology.

Authors:  Graham J Dockray; Andy Moore; Andrea Varro; D Mark Pritchard
Journal:  Curr Gastroenterol Rep       Date:  2012-12

Review 4.  Novel roles of gastrin.

Authors:  Rod Dimaline; Andrea Varro
Journal:  J Physiol       Date:  2014-03-24       Impact factor: 5.182

5.  Investigating the role of introns in the regulation of regenerating gene 1 expression.

Authors:  Yurong Chai; Yun Sun; Linxia Guo; Dan Li; Yi Ding
Journal:  Oncol Lett       Date:  2014-11-19       Impact factor: 2.967

Review 6.  The stomach in health and disease.

Authors:  R H Hunt; M Camilleri; S E Crowe; E M El-Omar; J G Fox; E J Kuipers; P Malfertheiner; K E L McColl; D M Pritchard; M Rugge; A Sonnenberg; K Sugano; J Tack
Journal:  Gut       Date:  2015-09-04       Impact factor: 23.059

7.  The role of plasminogen activator inhibitor-1 in gastric mucosal protection.

Authors:  Susan Kenny; Islay Steele; Suzanne Lyons; Andrew R Moore; Senthil V Murugesan; Laszlo Tiszlavicz; Rod Dimaline; D Mark Pritchard; Andrea Varro; Graham J Dockray
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-14       Impact factor: 4.052

8.  NR4A2 is regulated by gastrin and influences cellular responses of gastric adenocarcinoma cells.

Authors:  Kristine Misund; Linn-Karina Myrland Selvik; Shalini Rao; Kristin Nørsett; Ingunn Bakke; Arne K Sandvik; Astrid Lægreid; Torunn Bruland; Wenche S Prestvik; Liv Thommesen
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

9.  Gastric expression of plasminogen activator inhibitor (PAI)-1 is associated with hyperphagia and obesity in mice.

Authors:  Susan Kenny; Joanne Gamble; Suzanne Lyons; Nikolina Vlatkovic; Rod Dimaline; Andrea Varro; Graham J Dockray
Journal:  Endocrinology       Date:  2012-12-18       Impact factor: 4.736

10.  Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.

Authors:  Andrew R Moore; Malcolm Boyce; Islay A Steele; Fiona Campbell; Andrea Varro; D Mark Pritchard
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.